Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
MIMEDX (Nasdaq: MDXG) entered an exclusive distribution agreement with Summit Products Group on February 4, 2026 to add three 510(k) cleared surgical and wound-care products: Hydrelix, NovaForm, and G4Derm Plus.
The products include a soluble bovine collagen powder, a bioglass-collagen wound matrix, and a flowable peptide matrix designed to support wound healing and manage bioburden.
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.
The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.
Summary not available.
MiMedx (Nasdaq: MDXG) entered an exclusive U.S. distribution agreement with Regen Lab USA to distribute RegenKit®-Wound Gel, an autologous PRP and autologous thrombin serum wound gel, on Dec 22, 2025. The product concentrates growth factors, platelets, plasma proteins and nutrients in a fibrin scaffold and removes iron-laden red blood cells.
RegenKit was approved by FDA in 2022 and is covered nationally by CMS/LCD for diabetic chronic wounds under HCPCS code G0465. MiMedx says the kit adds a differentiated autologous option to its Advanced Wound Care portfolio and that upcoming LCD implementation on Jan 1, 2026 strengthens its competitive position.
MiMedx (NASDAQ: MDXG) announced a peer-reviewed publication on Dec 19, 2025 in the Journal of Inflammation reporting in vitro findings for Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts.
The study found that DHACM and LHACM exhibit multifactorial immunomodulatory effects on inflammatory monocytes and macrophages and enhance pro-reparative functions including efferocytosis and cell survival, suggesting potential to help reset the wound-healing cascade in complex wounds characterized by persistent inflammation.
MiMedx (Nasdaq: MDXG) reported interim results from the CAMPAIGN randomized controlled trial evaluating EPIEFFECT versus standard of care (SOC) for nonhealing diabetic foot ulcers. The interim analysis (71 patients) showed a posterior probability of superiority of 98.5% against a 90% success threshold. Results were published in the International Journal of Tissue Repair and an expanded 88-patient sample was presented at TRES on Oct 30, 2025. Enrollment is ongoing and MiMedx highlighted potential relevance for pending Medicare and commercial LCD implementations effective Jan 1, 2026.
MiMedx (Nasdaq: MDXG) announced that senior management will participate in two investor conferences in New York in November 2025.
Key details: Craig-Hallum 16th Annual Alpha Select Conference in New York on Tuesday, November 18, 2025 with 1:1 sessions, and Canaccord MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 with 1:1 sessions. Investors seeking meetings should contact their Craig-Hallum or Canaccord representative.
MiMedx (Nasdaq: MDXG) commented on the CY 2026 Physician Fee Schedule (PFS) final rule published by CMS on Nov 3, 2025. The company says the final rule is "essentially what was proposed in July" and believes the changes and other CMS initiatives aim to reduce industry fraud, waste and abuse, restoring stability and predictability to the market.
MiMedx states it is positioned to benefit from the reform given its scalable operations, commercial reach, technology, IP portfolio, and an excellent balance sheet, while noting details and mechanics still require review and some company recommendations were not adopted.
MIMEDX (Nasdaq: MDXG) reported record third-quarter 2025 results: net sales $114M (+35% YoY), GAAP net income $17M, diluted EPS $0.11, and adjusted EBITDA $35M (31% of net sales). Gross margin was 84% and cash and cash equivalents were $142M (net cash of $124M after debt). Management raised 2025 guidance to expect mid-to-high teens net sales growth and at least mid-20% full-year adjusted EBITDA margin. Company cited CMS 2026 reimbursement rules as an open factor and will host a conference call on Oct 29, 2025 at 4:30 PM ET.
MiMedx (Nasdaq: MDXG) will report third quarter operating and financial results for the period ended September 30, 2025 after market close on Wednesday, October 29, 2025. Senior management will host a webcast and conference call beginning at 4:30 p.m. Eastern Time the same day. U.S. and international dial-in numbers and a conference ID are provided, and a replay will be available on the company website for approximately 30 days.
FAQ
What is the current stock price of Mimedx Group (MDXG)?
What is the market cap of Mimedx Group (MDXG)?
